Market Cap 112.51M
Revenue (ttm) 149.96M
Net Income (ttm) -66.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -44.66%
Debt to Equity Ratio 0.00
Volume 735,500
Avg Vol 743,170
Day's Range N/A - N/A
Shares Out 63.21M
Stochastic %K 75%
Beta 1.61
Analysts Sell
Price Target $3.40

Company Profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which ha...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 251 5172
Fax: 301 251 5321
Address:
9704 Medical Center Drive, Rockville, United States
MarketWarfare
MarketWarfare Oct. 3 at 3:47 PM
$MGNX squashed over $1.80 every time. Let's fucking go already.
2 · Reply
PSDL75
PSDL75 Oct. 2 at 10:29 AM
$MGNX If we're all patient - that golden cross set up could be magical.....just saying
1 · Reply
PSDL75
PSDL75 Oct. 2 at 10:20 AM
$MGNX Just move already
0 · Reply
MarketWarfare
MarketWarfare Oct. 1 at 8:10 PM
$MGNX typical pop and fade like usual. It's actually absurd how poorly this piece of shit holds a gain. Short interest lowest it has been in 2 years.
1 · Reply
Budman10
Budman10 Oct. 1 at 2:12 PM
$MGNX not much discussion on the phase 1 Lori results. They were rather significant and positive. ORR at 26% and PSA50 response rare of 29% are solid results. Phase 2 hopfully wraps up in the next couple months.
0 · Reply
waterlock
waterlock Oct. 1 at 1:04 PM
$MGNX does anyone have an estimate on when the data will come out? I mean by calculating the last patient last visit.
0 · Reply
highnihilism
highnihilism Oct. 1 at 11:26 AM
$PLMR Palomar Trades: 7 | Total $: 32.1 K | 0.55 × 90-Day Avg $: 58.4 K | Call $: 706 | Put $: 31.4 K | Single-Leg: 100% | Multi-Leg: – | Contingent: – $BWEN Broadwind Trades: 7 | Total $: 706 | 0.22 × 90-Day Avg $: 3.2 K | Call $: 706 | Put $: 0 | Single-Leg: 100% | Multi-Leg: – | Contingent: – $MGNX Macrogenics Trades: 7 | Total $: 702 | 0.07 × 90-Day Avg $: 10.6 K | Call $: 702 | Put $: 0 | Single-Leg: 100% | Multi-Leg: – | Contingent: – $EPI WisdomTree India Earnings Trades: 7 | Total $: 1.8 K | 0.09 × 90-Day Avg $: 20.6 K | Call $: 700 | Put $: 1.1 K | Single-Leg: 100% | Multi-Leg: – | Contingent: –
0 · Reply
MarketWarfare
MarketWarfare Sep. 30 at 7:22 PM
$MGNX amazing how many stocks have popped hundreds and thousands of percent over the past year with ease and this piece of shit is down 50%. Management not even making a minimal effort.
1 · Reply
TheStocksDoc
TheStocksDoc Sep. 29 at 7:58 PM
$MGNX took a starter
0 · Reply
PSDL75
PSDL75 Sep. 29 at 3:58 PM
0 · Reply
Latest News on MGNX
MacroGenics: Working On That Road To Recovery

Jun 11, 2025, 6:32 PM EDT - 4 months ago

MacroGenics: Working On That Road To Recovery


MacroGenics to Participate in Upcoming Investor Conference

May 1, 2025, 4:30 PM EDT - 5 months ago

MacroGenics to Participate in Upcoming Investor Conference


MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:09 PM EDT - 7 months ago

MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript


MacroGenics: Stacking Up A Lot Of Headwinds

Feb 27, 2025, 2:08 PM EST - 7 months ago

MacroGenics: Stacking Up A Lot Of Headwinds


MacroGenics to Participate in Upcoming Investor Conferences

Feb 27, 2025, 7:30 AM EST - 7 months ago

MacroGenics to Participate in Upcoming Investor Conferences


MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

Nov 5, 2024, 7:01 PM EST - 11 months ago

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript


MacroGenics Announces Leadership Transition

Oct 30, 2024, 7:30 AM EDT - 1 year ago

MacroGenics Announces Leadership Transition


MarketWarfare
MarketWarfare Oct. 3 at 3:47 PM
$MGNX squashed over $1.80 every time. Let's fucking go already.
2 · Reply
PSDL75
PSDL75 Oct. 2 at 10:29 AM
$MGNX If we're all patient - that golden cross set up could be magical.....just saying
1 · Reply
PSDL75
PSDL75 Oct. 2 at 10:20 AM
$MGNX Just move already
0 · Reply
MarketWarfare
MarketWarfare Oct. 1 at 8:10 PM
$MGNX typical pop and fade like usual. It's actually absurd how poorly this piece of shit holds a gain. Short interest lowest it has been in 2 years.
1 · Reply
Budman10
Budman10 Oct. 1 at 2:12 PM
$MGNX not much discussion on the phase 1 Lori results. They were rather significant and positive. ORR at 26% and PSA50 response rare of 29% are solid results. Phase 2 hopfully wraps up in the next couple months.
0 · Reply
waterlock
waterlock Oct. 1 at 1:04 PM
$MGNX does anyone have an estimate on when the data will come out? I mean by calculating the last patient last visit.
0 · Reply
highnihilism
highnihilism Oct. 1 at 11:26 AM
$PLMR Palomar Trades: 7 | Total $: 32.1 K | 0.55 × 90-Day Avg $: 58.4 K | Call $: 706 | Put $: 31.4 K | Single-Leg: 100% | Multi-Leg: – | Contingent: – $BWEN Broadwind Trades: 7 | Total $: 706 | 0.22 × 90-Day Avg $: 3.2 K | Call $: 706 | Put $: 0 | Single-Leg: 100% | Multi-Leg: – | Contingent: – $MGNX Macrogenics Trades: 7 | Total $: 702 | 0.07 × 90-Day Avg $: 10.6 K | Call $: 702 | Put $: 0 | Single-Leg: 100% | Multi-Leg: – | Contingent: – $EPI WisdomTree India Earnings Trades: 7 | Total $: 1.8 K | 0.09 × 90-Day Avg $: 20.6 K | Call $: 700 | Put $: 1.1 K | Single-Leg: 100% | Multi-Leg: – | Contingent: –
0 · Reply
MarketWarfare
MarketWarfare Sep. 30 at 7:22 PM
$MGNX amazing how many stocks have popped hundreds and thousands of percent over the past year with ease and this piece of shit is down 50%. Management not even making a minimal effort.
1 · Reply
TheStocksDoc
TheStocksDoc Sep. 29 at 7:58 PM
$MGNX took a starter
0 · Reply
PSDL75
PSDL75 Sep. 29 at 3:58 PM
0 · Reply
PSDL75
PSDL75 Sep. 29 at 3:57 PM
0 · Reply
ibaian
ibaian Sep. 29 at 1:03 AM
$MGNX The ongoing Phase 2 LORIKEET study is a 150-patient randomized study evaluating lorigerlimab in combination with docetaxel vs. docetaxel alone in second-line, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). The study was fully enrolled in late 2024 and the Company expects to provide a clinical update in the second half of 2025.
0 · Reply
Stockpicker9
Stockpicker9 Sep. 27 at 8:42 AM
$MGNX two events till end of 2025 which could trigger money milestones and make the share price jump....
1 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 2:03 PM
$MGNX: TRADE PUT orders came through 348 @ 0.90, Strike 2.5, Exp 12/19/2025, Premium $31,320, Sentiment BULLISH
0 · Reply
PSDL75
PSDL75 Sep. 23 at 4:26 PM
$CRDF $MGNX flipping no volume...blah
1 · Reply
Budman10
Budman10 Sep. 22 at 8:34 PM
$MGNX Monkey games in after hours. How surprising. Drop today’s gain on 500 shares.
1 · Reply
SkyLonger
SkyLonger Sep. 22 at 7:09 PM
$MGNX more 👀need to be on this $BOXL
0 · Reply
Gunnar1
Gunnar1 Sep. 22 at 7:07 PM
$MGNX Next leg up in the making?
0 · Reply
SkyLonger
SkyLonger Sep. 22 at 7:01 PM
0 · Reply
AaronBobDale
AaronBobDale Sep. 22 at 6:30 PM
0 · Reply
GermanInvest
GermanInvest Sep. 21 at 9:44 AM
$MGNX i am buying aggressive now
0 · Reply
PSDL75
PSDL75 Sep. 19 at 3:51 PM
$CRDF $MGNX No continuation today?
1 · Reply